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Abstract
Background: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast
cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other
non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.
Methods: Incident breast cancer patients were identified from eight cancer registries and compiled through the
European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained
for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively.
Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-
specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts
using meta-analysis techniques. Dose–response analyses by number of prescriptions were also performed. Analyses
were repeated investigating propranolol use before cancer diagnosis.
Results: The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of
breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol
use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95%
CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose–response
relationship. There was also no association between propranolol use before breast cancer diagnosis and breast
cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10,
respectively). Similar null associations were observed for non-selective beta-blockers.
Conclusions: In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers
was not associated with improved survival.
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Background
Beta-blockers, used for heart disease and hypertension [1],
act by inhibiting beta-adrenergic receptors. Recent studies
have shown that breast cancer tissue expresses beta-
adrenergic receptors [2], particularly type 2 beta-adrenergic
receptors [3]. Numerous in-vitro studies have demonstrated
that beta-blockers can disrupt migratory activity and inhibit
angiogenesis of cancer cells [4, 5]. In particular, propranolol
appears to have potent anti-migratory and anti-angiogenic
properties as demonstrated in cancer cell lines and animal
models [4–10]. This preclinical evidence has led to calls for
randomised controlled trials of propranolol as adjuvant
therapy in breast cancer patients [11]; however, although
early phase trials are underway [12, 13], phase 3 trials have
not been conducted to date.
Only three observational studies have previously in-
vestigated the association between propranolol use
and breast cancer outcomes. In 2011, an Irish study
observed an 80% reduction in breast cancer-specific
mortality among patients who used propranolol in the
year prior to diagnosis [14]. No association was ob-
served between propranolol use after diagnosis and
breast cancer-specific mortality in an English study
[15] or between propranolol use after diagnosis and
breast cancer recurrence in a Danish study [16].
However, these studies had limited power because of
the small numbers of breast cancer patients using
propranolol, reflecting the low prevalence of propran-
olol use which in each study was under 5% [14–16].
Therefore, a need remains to further investigate pro-
pranolol (and other non-selective beta-blockers) and
survival in breast cancer patients to inform the deci-
sion on whether to conduct large phase 3 randomised
controlled trials of propranolol as adjuvant cancer
therapy in breast cancer patients.
Consequently, utilising the European Cancer Phar-
macoepidemiology Network [17], we conducted a
pooled analysis of eight cohorts of breast cancer pa-
tients from across Europe to examine whether use of
propranolol (or other non-selective beta-blockers) is
associated with improved breast cancer-specific and
all-cause mortality.
Methods
Data sources
Eight cohorts of breast cancer patients from across
Europe (including Belgium, Denmark, England, the
Netherlands, Northern Ireland, Republic of Ireland,
Scotland and Sweden) were compiled through the
European Cancer Pharmacoepidemiology Network
[17]. Characteristics of these cohorts are presented in
Table 1. The association between propranolol use and
cancer mortality was examined previously within the
English cohort [15] (although using a nested case–
control design) and the Republic of Ireland cohort
[14] (although this analysis did not investigate pro-
pranolol use after diagnosis, had shorter follow-up
and had substantially fewer cases). Cancer recurrence
was investigated previously in the Danish cohort [16]
(although the earlier analysis was based on fewer than
20% of the breast cancer patients included in the
present analysis and did not investigate mortality).
Previous studies have reported detailed descriptions of
the medication data available and/or linkages available
in the cohorts from Denmark [18–20], England [21],
the Netherlands [22, 23], Northern Ireland [24],
Belgium [25], Republic of Ireland [26], Scotland [27]
and Sweden [28, 29].
Inclusion criteria
All cohorts identified incident invasive breast cancer
patients from cancer registries. The year of diagnosis for
included breast cancer patients varied across the cohorts
from 1998 to 2012. Patients with other invasive cancer
diagnoses (apart from non-melanoma skin cancer) prior
to their breast cancer diagnosis were excluded.
Exposure
Propranolol and all non-selective beta-blocker use (includ-
ing propranolol, sotalol, timolol, nadolol, carvedilol, pin-
dolol, oxprenolol and labetolol) was ascertained from
electronic dispensing records in five cohorts, GP prescrib-
ing records in two cohorts and health insurance records
in one cohort (see Table 1).
Outcome
In seven of the cohorts, mortality was ascertained from
national death records; social security records were used
in one cohort (see Table 1). Breast cancer-specific mortal-
ity was defined as breast cancer being the underlying
cause of death and was available in five cohorts. All-cause
mortality was available in all cohorts.
Covariates
The covariates available varied between cohorts and
were obtained from a number of sources including can-
cer registries, hospital admissions, prescriptions, GPs
and health insurance databases (see Table 1). The covari-
ates recorded included: age, year of cancer diagnosis,
stage, grade, cancer treatment within the first 6 months
after diagnosis (including information on cancer-
directed surgery, chemotherapy, radiotherapy), medica-
tion use (including tamoxifen, aromatase inhibitors, hor-
mone replacement therapy (prior to diagnosis), aspirin
[30], statins [31]) and comorbidities prior to diagnosis.
Cancer-directed surgery, chemotherapy and radiotherapy
were taken from cancer registry records, apart from in
Belgium where insurance claims were used and in
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Table 1 Characteristics of the included cohorts
Country Breast cancer Medication
data
Mortality data Additionala confounders
source Diagnosis
years
source source End
f-up
Mean f-up
(years)
Max f-up
(years)
BC specific Grade Surg Radio Chemo Tam AI Asp/
statin
HRT Comorbidity
Belgium Belgian Cancer
Registry
2007–2009 Intermutualistic
Agency (health
insurance
records)
Kruispuntbank
van de Sociale
Zekerheid (social
security records)
2014 6 8 No Yes Yes Yes Yes Yes Yes Yes Yes No
Denmark Danish Cancer
Registryb
2000–2012 Danish
National
Prescription
Registry
Danish Civil
Registration
System
2012 6 13 No Yes Yes Yes Yes Yes Yes Yes Yes Yesc
England (UK) National Cancer
Data Repository
1998–2007 CPRD
(GP records)
Office of National
Statistics
2011 6 12 Yes Yes Yes Yes Yes Yes Yes Yes No Yesd
The
Netherlands
Eindhoven
Cancer Registry
1999–2011 PHARMO
(pharmacy
records)
Central Bureau
of Genealogy
2012 6 13 No Yes Yes Yes Yes Yes Yes Yes Yes Yesg
Northern
Ireland (UK)
Northern Ireland
Cancer Registry
2009–2010 NIEPD
(electronic
dispensing
database)
General Register
Office for Northern
Ireland
2013 4 5 Yes No Yes N Yes Yes Yes Yes No No
Republic of
Ireland
National Cancer
Registry Ireland
2001–2010 GMSe
(electronic
prescribing
database)
Central Statistics
Office (Death
Certificates)
2012 5 11 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yesf
Scotland (UK) Scottish Cancer
Registry
2009–2012 Prescribing
Information
System
(electronic
dispensing
database)
National Records
of Scotland Death
Records
2015 4 6 Yes Yes Yes Yes Yes Yes Yes Yes No Yesc
Sweden Regional cancer
registries in Norra,
Uppsala/Örebro
Stockholm/Gotland
2007–2012 The Prescribed
Drug Register
Cause of death
registry
2012 4 6 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yesc
aIn fully adjusted analyses (presented in Tables 2 and 3), the model contains age at diagnosis, year of diagnosis, stage and the variables shown
bOnly including stages 1–3
cBased on hospital admissions
dBased on GP diagnosis codes
eGMS includes eligible patients based upon means test and age (all patients over 70 years old are included)
fBased on RxRisk comorbidity score
gFrom cancer registry records
AI aromatase inhibitors, asp aspirin, BC breast cancer, chemo chemotherapy, CPRD clinical practice research datalink, f-up follow-up duration from diagnosis to death or censoring, GMS General Medical Services scheme,
GP general practitioner, HRT hormone replacement therapy, max maximum, NIEPD Northern Ireland Electronic Prescribing Database, radio radiotherapy, surg surgery, tam tamoxifen
C
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Denmark where Patient Registry records were used.
Comorbidities, largely including those in the Charlson
comorbidity index [32], were taken from hospital admis-
sion records in Denmark, Scotland and Sweden, from
GP records in England and from cancer registry records
in the Netherlands. In the cohorts from the Netherlands,
Denmark and England, adjustments for comorbidity
were made for cerebrovascular disease, chronic pulmon-
ary disease, congestive heart disease, diabetes, myocar-
dial infarction, peptic ulcer disease, peripheral vascular
disease and renal disease. In Sweden additional adjust-
ments were made for liver disease and in Scotland add-
itional adjustments were made for liver disease and
diabetes complications. In the Republic of Ireland co-
hort, comorbidity information was based upon prescrib-
ing information using the RxRisk score [33]. Oestrogen
use was based upon HRT use any time prior to diagnosis
in the Netherlands, HRT or oral contraceptive use in the
year prior to diagnosis in Denmark or HRT use in the
year prior to diagnosis in Sweden, the Republic of
Ireland, Belgium and Scotland. Tamoxifen and aroma-
tase inhibitor use was obtained from prescription
records, except in Denmark were a single more
complete endocrine therapy variable, based upon Patient
Registry records, was used instead.
Statistical analysis
We performed a two-stage analysis procedure allow-
ing for adjustment of covariates which were not uni-
formly defined, coded or available across cohorts [34].
In the main analysis of medication use after diagnosis,
the patients in each cohort were followed from 1 year
after breast cancer diagnosis to death or end of
follow-up, whichever was sooner. Patients who had
died in the first year after breast cancer diagnosis (or
who had less than 1 year of follow-up) were excluded
because it seemed unlikely that propranolol use after
diagnosis could reduce mortality within such a short
period. In the main analysis, propranolol use was
modelled as a time-varying covariate to avoid immor-
tal time bias [35]; that is, patients were initially con-
sidered non-users and then became users a lag of
1 year after their first propranolol prescription. The
use of a lag period is recommended in studies of
medication use and cancer survival [36] because pre-
scriptions filled shortly prior to death may reflect
end-of-life treatment. In dose–response analyses, one
propranolol prescription corresponded to 1 month of
use, except for Denmark where one prescription cor-
responded to 3 months of use (based on the average
duration of propranolol prescriptions in Denmark). In
dose–response analyses, an individual was considered
a non-user prior to 1 year after first medication
usage, a user of 0–1 year for prescriptions from 1 year
after first prescription to 1 year of prescriptions (con-
sidered four prescriptions in Denmark and 12 pre-
scriptions in all other countries) and a greater user
after this time. Time-dependent Cox regression
models were used to calculate hazard ratios (HRs)
and 95% confidence intervals (CIs) for breast cancer-
specific death in propranolol users compared with
propranolol non-users. An unadjusted analysis was
first conducted, then an adjusted analysis (including
just the covariates age and year of diagnosis in the
model, which were available in all cohorts) and finally
a fully adjusted analysis was conducted (including all
covariates available within each cohort, as presented
in Table 1, in the model). The summary HRs and
standard errors (SEs) from the eight cohorts were
combined using random effects models to calculate
pooled HRs [37] and the consistency of HRs was in-
vestigated using chi-squared tests for heterogeneity
and I2 statistics [38]. The analyses were repeated for
all-cause mortality. Analyses were then repeated com-
paring all non-selective beta-blockers users with non-
selective beta-blocker non-users and comparing all
beta-blocker users with beta-blocker non-users. A
sensitivity analysis was conducted restricting the co-
horts to patients with stage 1–3 breast cancer, be-
cause it is plausible that the effect might be most
evident in those without advanced disease.
We performed two predefined secondary analyses.
First, avoiding immortal time bias without requiring
complex analyses [39], we compared users of pro-
pranolol (and separately users of non-selective beta-
blockers) within the first year after breast cancer
diagnosis with non-users within the same period, and
started follow-up 1 year after breast cancer diagnosis.
Second, to investigate the potential impact of pro-
pranolol use earlier in the process of cancer develop-
ment, we performed a separate analysis of medication
use before breast cancer diagnosis comparing time to
death in propranolol (and non-selective beta-blockers)
users with non-users in the year prior to diagnosis,
restricted to individuals with at least 1 year of medi-
cation records prior to diagnosis. In analysis of pre-
diagnostic medication use, patients who died in the
first year after diagnosis (who had follow-up of less
than 1 year) were not excluded.
Results
Patient cohorts
The pooled analysis for breast-cancer specific and all-
cause mortality comprised 55,252 newly diagnosed
breast cancer patients (in whom there were 5419 breast
cancer-specific deaths and 9295 all-cause deaths) and
133,251 newly diagnosed breast cancer patients (in
whom there were 25,472 all-cause deaths), respectively.
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Table 2 Characteristics of breast cancer patients by propranolol and non-selective beta-blocker use in the year after diagnosis
Propranolol in year after diagnosisa Non-selective beta-blocker in year after diagnosisa
Characteristic Users Non-usersb Users Non-usersc
n % n % n % n %
Country
Belgium 984 35.7 25,021 19.2 2131 42.1 23,874 18.6
Denmark 615 22.3 44,049 33.8 1198 23.6 43,466 33.9
England 212 7.7 9602 7.4 299 5.9 9515 7.4
The Netherlands 78 2.8 7252 5.6 203 4.0 7130 5.6
Northern Ireland 70 2.5 2106 1.6 82 1.6 2094 1.6
Republic of Ireland 142 5.2 9720 7.4 250 4.9 9612 7.5
Scotland 400 14.5 14,740 11.3 468 9.2 14,672 11.4
Sweden 255 9.3 18,005 13.8 436 8.6 17,824 13.9
Year of cancer diagnosis
1995–1999 61 2.2 2495 1.9 84 1.7 2472 1.9
2000–2004 480 17.4 27,621 21.2 832 16.4 27,269 21.3
2005–2009 1 572 57.0 66,186 50.7 3219 63.5 64,542 50.3
2010–2014 643 23.3 34,193 26.2 932 18.4 33,904 26.4
Age at cancer diagnosis
<40 97 3.5 5591 4.3 110 2.2 5578 4.4
40–49 444 16.1 19,688 15.1 540 10.7 19,592 15.3
50–59 730 26.5 31,297 24.0 1031 20.3 30,996 24.2
60–69 768 27.9 35,528 27.2 1419 28.0 34,877 27.2
70–79 491 17.8 23,488 18.0 1235 24.4 22,744 17.7
80–89 200 7.3 12,974 9.9 647 12.8 12,527 9.8
≥90 26 0.9 1929 1.5 82 1.6 1873 1.5
Stage
1 965 35.0 49,458 37.9 1735 34.2 48,669 38.0
2 927 33.6 41,797 32.0 1718 33.9 41,006 32.0
3 284 10.3 9073 7.0 510 10.1 8847 6.9
4 138 5.0 5086 3.9 258 5.1 4966 3.9
Missing 442 16.0 25,081 19.2 843 16.6 24,699 19.3
Grade
Well differentiated 365 17.2 16,827 19.7 662 17.2 16,530 19.7
Moderately differentiated 885 41.6 34,600 40.5 1543 40.2 33,942 40.5
Poorly differentiated 639 30.0 22,964 26.9 1109 28.9 22,494 26.8
Missing 239 11.2 11,115 13.0 529 13.8 10,825 12.9
Cancer treatment within 6 months of cancer diagnosis
Surgery 2 425 88.0 114,271 87.6 4387 86.6 112,309 87.7
Chemotherapy 1 034 37.6 46,018 35.3 1608 31.8 45,444 35.5
Radiotherapyd 1 463 54.6 68,817 53.7 2649 53.2 67,631 53.7
Medication use in year after diagnosis
Aromatase inhibitore 724 33.8 29,176 33.8 1459 37.7 28,441 33.6
Tamoxifene 1 064 49.7 39,087 45.2 1765 45.6 38,386 45.3
Statin 532 19.3 22,245 17.0 1353 26.7 21,424 16.7
Low-dose aspirin 368 13.4 17,545 13.4 1097 21.6 16,816 13.1
aRestricted to breast cancer patients living more than 1 year after diagnosis
bPropranolol non-users in the year after diagnosis, but could have used other beta-blockers
cNon-selective beta-blocker non-users in the year after diagnosis, but could have used other beta-blockers
dRefers to radiotherapy within 6 months of breast cancer diagnosis, except in Belgium where radiotherapy was considered within 9 months
eExcluding Denmark because aromatase inhibitor and tamoxifen were not recorded separately
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The maximum follow-up in each cohort after diagnosis
of breast cancer ranged from 5 to 13 years (see Table 1).
Patient characteristics
Patient characteristics by propranolol (and non-
selective beta-blocker) use in the first year after diag-
nosis are presented in Table 2. Propranolol users were
slightly more likely to have an earlier year of breast
cancer diagnosis. Age, stage, grade and cancer treat-
ments were generally similar by propranolol use.
There was a higher use of hormone antagonists (tam-
oxifen 39% versus 30% and aromatase inhibitors 26%
versus 23%, respectively) in propranolol users versus
non-users, but use of other medications was similar.
Association between propranolol use after diagnosis and
breast cancer-specific and all-cause mortality
Overall 4746 breast cancer patients used propranolol
at any time after diagnosis (1768 from Belgian, 1057
from Denmark, 419 from England, 151 from the
Netherlands, 107 from Northern Ireland, 232 from
the republic of Ireland, 629 from Scotland and 383
from Sweden). Table 3 and Fig. 1 present the findings
from the main analysis. Overall, there was little differ-
ence in breast cancer-specific mortality or all-cause mortal-
ity in propranolol users compared with non-users after
diagnosis (fully adjusted HR= 0.94, 95% CI, 0.77, 1.16 and
HR= 1.09, 95% CI, 0.93, 1.28, respectively). The associa-
tions between propranolol and cancer-specific mortality
were fairly consistent across cohorts (I2 = 0% and hetero-
geneity P = 0.56), whereas the association varied more for
all-cause mortality (I2 = 65% and heterogeneity P = 0.006).
On closer inspection (see Fig. 1) this heterogeneity was
partly due to the Belgian estimate; once this was removed
the pooled estimate was attenuated slightly (fully adjusted
HR= 1.03, 95% CI, 0.88, 1.20) and the heterogeneity was re-
duced (I2 = 39% and heterogeneity P = 0.02). There was lit-
tle evidence of a dose–response association; compared with
propranolol non-users, there was no association between
use of more than 1 year of propranolol prescriptions and
cancer-specific or all-cause mortality (fully adjusted HR=
0.93, 95% CI, 0.46, 1.90 and HR= 1.09, 95% CI, 0.85, 1.40,
respectively). Similar null associations were observed for
cancer-specific mortality when comparing users of non-
selective beta-blockers with non-users of non-selective
beta-blockers (see Table 3).
Secondary and sensitivity analyses
Secondary and sensitivity analyses are presented in
Table 4. In sensitivity analyses restricting the cohorts
to stage 1–3 breast cancer patients only, the associa-
tions between propranolol and cancer-specific and all-
cause mortality was similar to those for the main ana-
lysis (see Table 4). In secondary analysis there was no
evidence of an inverse association between any beta-
blocker use after diagnosis and cancer-specific or all-
cause mortality (fully adjusted HR = 1.07, 95% CI,
0.99, 1.16 and HR = 1.12, 95% CI, 1.05, 1.20, respect-
ively). The secondary analysis based upon medication
use in the first year after diagnosis also produced
similar results for propranolol and cancer-specific and
all-cause mortality (fully adjusted HR = 1.07, 95% CI,
0.72, 1.60 and HR = 1.04, 95% CI, 0.89, 1.21,
respectively).
Table 4 also presents results for the analysis of pro-
pranolol use before diagnosis. Propranolol use in the
year before diagnosis was not associated with reduced
cancer-specific or all-cause mortality (fully adjusted HR
= 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94,
1.10, respectively). In all secondary analyses of non-
selective beta-blocker use, similar associations were ob-
served to those for propranolol use (see Table 4).
Discussion
This large pooled analysis of breast cancer patients did
not present convincing evidence of reduced cancer-
specific or all-cause mortality in breast cancer patients
who used propranolol or non-selective beta-blockers ei-
ther before or after breast cancer diagnosis.
Our pooled analysis supports the findings of two earlier
epidemiological studies of the association between pro-
pranolol use after diagnosis and cancer outcomes [15, 16].
The first, an earlier analysis of Danish data [16], showed no
association between propranolol use after diagnosis and re-
currence (adjusted HR = 1.3, 95% CI, 0.92, 1.9); however,
that study did not investigate mortality or the influence of
propranolol use before diagnosis. The second study, an
earlier analysis of English data [15], based upon a case–
control design, showed no association between propranolol
and cancer-specific mortality (adjusted HR = 0.98, 95% CI,
0.57, 1.71).
Our pooled analysis also showed no reduction in cancer-
specific mortality associated with propranolol use before
diagnosis and therefore does not support the results of an
earlier Irish study, the only previous study to investigate
this association, which observed an 80% reduction in breast
cancer-specific mortality (adjusted HR= 0.19, 95% CI, 0.06
0.60) in 46 breast cancer patients using propranolol in the
year prior to diagnosis [14].
The main strength of our analysis is statistical power;
this is the largest study yet to investigate the association
between use of propranolol and cancer outcomes in
breast cancer patients. Despite this, there remains the
possibility of type 2 error and we cannot rule out a weak
protective effect of propranolol on cancer-specific mor-
tality. Other strengths include the long duration of
follow-up, which was up to 13 years following breast
cancer diagnosis in some cohorts. The use of routinely
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Table 3 Pooled analysis of the association between propranolol and non-selective beta-blocker use after breast cancer diagnosis and breast cancer-specific and all-cause mortality
Medication usage Cancer-specific/
all-cause mortality
All
patients
Person-
years
Unadjusted Adjusted for age and year Fully adjusteda
HR (95% CI) P Hetero I2 (P) HR (95% CI) P Hetero I2 (P) HR (95% CI) P Hetero I2 (P)
Breast cancer-specific mortality
Propranolol non-user 5291 53,482 176,723 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
Propranolol userb 128 1770 4989 0.92 (0.77, 1.10) 0.36 0% (0.75) 0.97 (0.82, 1.16) 0.77 0% (0.84) 0.94 (0.77, 1.16) 0.56 0% (0.56)
Propranolol prescriptions
<1 year of
prescriptionsc
88 1217 3703 1.00 (0.79, 1.26) 0.98 22% (0.27) 1.09 (0.88, 1.35) 0.42 9% (0.35) 1.01 (0.80, 1.27) 0.96 0% (0.62)
≥1 year of prescriptionsc 40 553 1286 0.82 (0.56, 1.21) 0.32 3% (0.38) 0.80 (0.54, 1.17) 0.25 2% (0.38) 0.93 (0.46, 1.90) 0.84 63% (0.04)
Non-selective bb non-user 5215 52,903 175,007 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
Non-selective bb userb 204 2349 6706 1.08 (0.94, 1.24) 0.31 0% (0.51) 1.07 (0.93, 1.23) 0.37 0% (0.92) 1.01 (0.85, 1.20) 0.90 0% (0.47)
Non-selective bb prescriptions
<1 year of prescriptionsc 145 1466 4555 1.13 (0.93, 1.37) 0.22 22% (0.27) 1.16 (0.99, 1.37) 0.07 0% (0.55) 1.10 (0.90, 1.34) 0.36 0% (0.70)
≥1 year of prescriptionsc 59 883 2149 1.02 (0.78, 1.31) 0.91 0% (0.72) 0.92 (0.71, 1.19) 0.53 0% (0.83) 0.97 (0.63, 1.48) 0.88 46% (0.14)
All-cause mortality
Propranolol non-user 24,654 128,505 554,765 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
Propranolol userb 818 4746 16,202 1.04 (0.86, 1.27) 0.68 82% (<0.01) 1.13 (0.93, 1.37) 0.21 81% (<0.01) 1.09 (0.93, 1.28) 0.27 65% (0.006)
Propranolol prescriptions
<1 year of prescriptionsc 548 3099 10,977 1.01 (0.78, 1.32) 0.92 85% (<0.01) 1.20 (0.93, 1.53) 0.16 83% (<0.01) 1.15 (0.95, 1.39) 0.16 62% (0.01)
≥1 year of prescriptionsc 270 1647 5225 1.18 (0.97, 1.44) 0.10 45% (0.09) 1.10 (0.96, 1.26) 0.17 10% (0.35) 1.09 (0.85, 1.40) 0.48 55% (0.04)
Non-selective bb non-user 23,740 125,320 543,344 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
Non-selective bb userb 1732 7931 27,624 1.34 (1.14, 1.58) 0.001 87% (<0.01) 1.22 (1.09, 1.36) 0.001 70% (<0.01) 1.16 (1.02, 1.32) 0.02 71% (<0.01)
Non-selective bb prescriptions
<1 year of prescriptionsc 1012 4512 17,074 1.23 (0.98, 1.55) 0.08 89% (<0.01) 1.22 (1.04, 1.43) 0.02 75% (<0.01) 1.19 (1.04, 1.36) 0.01 54% (0.03)
≥1 year of prescriptionsc 720 3419 10,549 1.67 (1.49, 1.87) <0.001 39% (0.13) 1.30 (1.21, 1.40) <0.001 0% (0.61) 1.23 (1.04, 1.45) 0.02 62% (0.02)
aModel contains age, year, stage and confounders presented in Table 1
bMedication use modelled as a time-varying covariate with an individual considered a non-user prior to 1 year after first medication usage and a user after this time, excludes deaths in the year after cancer diagnosis
cMedication use modelled as a time-varying covariate with an individual considered a non-user prior to 1 year after first medication usage, a user of 0–1 year of prescriptions from 1 year after first prescription to 1 year
of prescriptions (considered four prescriptions in Denmark and 12 prescriptions in all other countries) and a greater user after this time, excludes deaths in the year after cancer diagnosis
bb beta-blocker, CI confidence interval, HR hazard ratio, ref. cat. reference category
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recorded drug information allowed precise evaluations
of temporal relationships between propranolol use and
mortality and eliminated the potential for recall bias in-
curred in questionnaire-based studies. Misclassification
due to over-the-counter use was likely to be minimal
because propranolol can be obtained only by prescrip-
tion in the included countries.
A weakness of the study is the potential for bias
due to the misclassification of breast cancer-specific
cause of death on death certificates. However, simula-
tions from a recent methodological study indicate that
misclassification of breast cancer-specific cause of
death is likely to have relatively small impact on com-
parisons between groups, assuming misclassification
of cancer-specific death is not differential [40]. It
should be noted that cohorts from three of the con-
tributing countries [14–16] had been analysed previ-
ously with respect to propranolol; however, over 80%
of the breast cancer patients included in the pooled
analysis had not been analysed previously, and these
earlier analyses covered different time periods [14,
16], were based on different study designs [14, 15],
used a different outcome [16] or investigated only ex-
posure before diagnosis [14]. There were some differ-
ences in the ascertainment of medication use (five
studies used dispensing records, two used GP pre-
scribing records and one used health insurance re-
cords) and in the ascertainment of mortality (seven
studies used national mortality records and one used
social security records). These differences may have
contributed to the heterogeneity of the association be-
tween propranolol and all-cause mortality. This was
partly due to the estimate in the Belgian cohort, and
after removal of this study the heterogeneity was
markedly reduced, but findings for all-cause mortality
were similar. In contrast, there was little evidence of
heterogeneity in the association between propranolol
and cancer-specific mortality.
Oestrogen receptor status was not available in all of
the cohorts; however, reanalysis of the propranolol
association in the Swedish and Scottish cohorts add-
itionally adjusting for oestrogen receptor status (after
including tamoxifen and aromatase inhibitors in the
model) made little difference to the estimates (data
not shown), suggesting that oestrogen receptor status
had limited potential to confound our results. BMI
was also not available. The lack of adjustment for
BMI could have attenuated propranolol associations
because breast cancer patients with higher BMI have
worse survival [41]. Similarly, we cannot rule out the
effect of residual confounding on the observed associ-
ations from other unrecorded variables (such as tras-
tuzumab use, diet, alcohol intake and physical
activity) or for variables which were recorded differ-
ently between cohorts (such as use of hormone
replacement therapy).
Conclusions
In this large pooled analysis, propranolol and non-selective
beta-blocker use, either before or after diagnosis, was not
Fig. 1 Association between propranolol and breast cancer-specific and all-cause mortality, by cohort. *Fully adjusted model contains age, year,
stage and confounders presented in Table 1. CI confidence interval, HR hazard ratio
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associated with improved breast cancer-specific or all-cause
mortality.
Abbreviations
CI: Confidence interval; GP: General practitioner; HR: Hazard ratio;
SE: Standard error
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Table 4 Secondary and sensitivity analyses for pooled analysis of the association between propranolol and non-selective beta-blocker
use and breast cancer-specific and all-cause mortality
Medication usage Deaths Patients Person-years Unadjusted Fully adjusted
HR (95% CI) P Hetero I2 (P) Adjusted HR (95% CI) P Hetero I2 (P)
Breast cancer-specific mortality
Medication use after diagnosis
Main time-varying covariate analysis in stage 1–3 breast cancer patients
Propranolol in stages 1–3 3389 44,376 112,450 1.02 (0.82, 1.26) 0.88 0% (0.84) 1.06 (0.85, 1.33) 0.62 0% (0.60)
Main time-varying covariate analysis in all breast cancer patients
Any beta-blocker 5419 55,252 181,714 1.25 (1.11, 1.40) <0.001 63% (0.03) 1.07 (0.99, 1.16) 0.10 0% (0.82)
Analysis based upon use in year after diagnosisa
Propranolol 5426 55,252 181,959 0.94 (0.72, 1.21) 0.61 35% (0.19) 1.07 (0.72, 1.60) 0.72 65% (0.02)
Non-selective beta-blocker 5426 55,252 181,959 1.10 (0.87, 1.39) 0.43 51% (0.09) 1.15 (0.85, 1.56) 0.35 60% (0.04)
Medication use before diagnosisb
Propranolol 6883 53,870 215,978 0.97 (0.82, 1.15) 0.73 0% (0.51) 1.03 (0.86, 1.22) 0.78 3% (0.39)
Non-selective beta-blocker 6883 53,870 215,978 1.09 (0.95, 1.25) 0.22 0% (0.47) 1.05 (0.92, 1.21) 0.45 0% (0.68)
All-cause mortality
Medication use after diagnosis
Main time-varying covariate analysis in stage 1–3 breast cancer patients
Propranolol in stages 1–3c 17,219 96,097 382,1512 1.07 (0.93, 1.24) 0.32 29% (0.21) 1.13 (1.02, 1.24) 0.02 0% (0.46)
Main time-varying covariate analysis in all breast cancer patients
Any beta-blocker 25,472 133,251 570,968 1.57 (1.41, 1.75) <0.001 92% (<0.001) 1.12 (1.05, 1.20) <0.001 65% (0.006)
Analysis based upon use in year after diagnosisa
Propranolol 25,487 133,251 571,213 1.02 (0.89, 1.16) 0.82 48% (0.06) 1.04 (0.89, 1.21) 0.62 48% (0.06)
Non-selective beta-blocker 25,487 133,251 571,213 1.35 (1.17, 1.55) <0.001 78% (<0.001) 1.14 (0.99, 1.30) 0.06 68% (0.003)
Medication use before diagnosisb
Propranolol 31,556 139,760 664,448 0.97 (0.86, 1.09) 0.60 44% (0.09) 1.02 (0.94, 1.10) 0.68 0% (0.54)
Non-selective beta-blocker 31,556 139,760 664,448 1.30 (1.14, 1.49) <0.001 80% (<0.001) 1.13 (1.06, 1.21) <0.001 27% (0.21)
aSimplified analysis, not requiring time-varying covariate use, comparing medication users with non-users in the first year after diagnosis in individuals living more
than 1 year after cancer diagnosis; fully adjusted column adjusted for age, year, stage and all confounders presented in Table 1
bBased on use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to diagnosis; fully adjusted column only adjusted for age at
diagnosis and year of diagnosis
cExcludes the Belgian cohort
CI confidence interval, HR hazard ratio
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